Tirzepatide denied as non-formulary by Anthem?

Anthem's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denies Tirzepatide as Non-Formulary

Anthem places tirzepatide on a formulary tier that requires prior authorization, or in some plan designs excludes it from covered drugs entirely for certain indications. A non-formulary denial means the plan's drug list does not include tirzepatide at a covered tier without additional approval steps, or that the specific indication being treated is excluded from the formulary benefit. This is a coverage-design decision, not a clinical judgment — and it is one of the most commonly overturned denial types on appeal.

## Your Federal Appeal Rights

• ACA §2719 / External Review: After exhausting internal appeals, most ACA-compliant plans must offer Independent Review Organization (IRO) external review. Review your denial letter carefully for the external-review deadline, which is typically around four months from the final internal denial date.
• ERISA §503: ERISA plans must provide full and fair review, including disclosure of the formulary exception criteria applied.
• Formulary Exception Process: Separate from the standard appeal, most plans have a formulary exception pathway that can run in parallel. A successful exception converts tirzepatide to a covered tier without requiring full appeal exhaustion.
• Expedited Review: Available if your health condition is urgent or treatment interruption would cause serious harm.

## Appeal and Exception Timeline

1. Simultaneously file a formulary exception request and a standard internal appeal — they are complementary, not mutually exclusive. 2. The formulary exception request should come directly from your prescriber and explain why formulary alternatives are clinically inappropriate for your specific situation. 3. Internal appeals are typically decided within 30 days (pre-service) or 60 days (post-service). 4. If both are denied, request external review from the IRO identified in your denial letter.

## Documentation to Gather

• Formulary alternative trial history: For each drug on Anthem's preferred formulary tier for your condition, document the dates tried, response, and the specific clinical reason it was inadequate or contraindicated for this patient — per the prescriber's clinical judgment and chart notes.
• Prescriber formulary exception letter: A letter explaining the medical reason tirzepatide is necessary rather than the preferred formulary agent, citing the patient's individual clinical circumstances.
• Diagnosis and severity documentation: Chart notes, lab results, and specialist records confirming diagnosis and current clinical status.
• FDA labeling alignment: Confirm with your prescriber that your indication aligns with tirzepatide's FDA-approved label, and document that in the appeal.

## Criteria-Mapping Structure

Anthem's formulary exception criteria typically include a requirement that preferred alternatives have been tried and failed, or that they are contraindicated. Obtain the exact exception criteria from Anthem's published formulary exception policy. For each criterion, cite the specific chart entry that addresses it. Where a formulary alternative was never tried, your prescriber must explain on clinical grounds — not just preference — why it would be inappropriate. A clear, requirement-by-requirement response is far more effective than a narrative letter alone.